Iradimed (IRMD) EBIT (2013 - 2026)

Iradimed (IRMD) has reported EBIT for 14 consecutive years, with $6.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT fell 5.85% year-over-year to $6.4 million in Q2 2026; TTM through Jun 2026 was $27.6 million, a 15.73% increase from a year earlier, with the FY2025 full-year figure at $26.1 million, up 19.04% from the prior year.
• EBIT was $6.4 million for Q2 2026 at Iradimed, down from $7.2 million in the prior quarter.
• Over five years, EBIT peaked at $7.2 million in Q1 2026 and troughed at $3.1 million in Q1 2022.
• A 5-year average of $5.4 million and a median of $5.5 million in 2024 frame the typical range for EBIT.
• Across the five-year window, EBIT soared 125.93% in 2022 and dropped 5.85% in 2026, its largest moves.
• Over 5 years, EBIT stood at $4.3 million in 2022, then rose by 21.3% to $5.2 million in 2023, then grew by 12.42% to $5.8 million in 2024, then grew by 22.3% to $7.1 million in 2025, then decreased by 9.91% to $6.4 million in 2026.
• The last three EBIT figures came in at $6.4 million (Q2 2026), $7.2 million (Q1 2026), and $7.1 million (Q4 2025), per Business Quant data.